Z 13752A
Alternative Names: GW 660511XLatest Information Update: 05 Nov 2002
At a glance
- Originator Zambon Group SpA
- Developer GlaxoSmithKline
- Class
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 05 Nov 2002 Discontinued - Phase-II for Hypertension in United Kingdom (unspecified route)
- 30 Apr 2002 Phase-II clinical trials in Hypertension in United Kingdom (unspecified route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline